Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | ITK | Q08881 | 4/20 | 0.48 |
| ▸ | PPIF | P30405 | 1/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24969094 | 0.89 | EGFR (0.61) | EGFRERBB2ERBB4ITKLRRK2 | |
| SCHEMBL24968812 | 0.87 | EGFR (0.54) | EGFRERBB2ERBB4ITKLRRK2 | |
| SCHEMBL24968503 | 0.87 | EGFR (0.52) | EGFRERBB2ERBB4MRGPRX4ITK | |
| SCHEMBL30152264 | 0.87 | EGFR (0.52) | EGFRERBB2ERBB4MRGPRX4ITK | |
| SCHEMBL24969052 | 0.87 | EGFR (0.55) | EGFRERBB2ERBB4MRGPRX4ITK | |
| SCHEMBL24969100 | 0.86 | EGFR (0.47) | EGFRERBB2ERBB4ITKLRRK2 | |
| SCHEMBL24969151 | 0.85 | S1PR1 (0.52) | EGFRERBB2ERBB4MRGPRX4ITK | |
| SCHEMBL24968513 | 0.84 | DHODH (0.50) | EGFRERBB2ERBB4ITK | |
| SCHEMBL24969149 | 0.84 | EGFR (0.48) | EGFRERBB2ERBB4MRGPRX4ITK | |
| SCHEMBL24969106 | 0.84 | EGFR (0.48) | EGFRERBB2ERBB4MRGPRX4ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |